Women With Polycystic Ovary Syndrome (PCOS)

Irmandade da Santa Casa de Misericordia de Sao Paulo

Status: Unknown

Conditions: Polycystic Ovary Syndrome

Study type: Observational

Funder types: Other

Identifiers

NCT02467751

167/10

Details and patient eligibility

About

Metabolic profile in women of different body composition with polycystic ovary syndrome.

Full description

Will be performed case-control study with women with Polycystic Ovary Syndrome, according to the Rotterdam criteria and body mass index between 18 to 29.9. The control group will consist of women without Polycystic Ovary Syndrome, with a body mass index of 18 to 29.9 and no other comorbidities. In both groups collect anthropometric data such as age, weight, height, waist circumference and blood pressure. Exams will be requested: metabolic profile (total cholesterol (mg/dL) and fractions, triglycerides (mg/dL), blood count, liver function (U/L) and classical glycemic index (mg/dL); hormonal profile - insulin (uIU/ml), luteinizing hormone (IU/L), follicle stimulating hormone (IU/L), thyreostimulating hormone (uIU/ML), total and free testosterone (ng/ml), 17-hydroxyprogesterone (ng/ml), dehydroepiandrosterone (ng/ml), prolactin (ug/ml). Body composition (BMI) will be performed by absorption technique of two low energy beams emitted by X-ray - full body densitometry (DEXA). Expected result: To evaluate visceral fat and truncal of patients with diagnosis of Polycystic Ovary Syndrome without obesity.

Enrollment: 90 estimated patients

Sex: Female

Ages: 12 to 39 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Polycystic Ovary Syndrome , body mass index of 18 to 29.9, without contraceptive use.

Exclusion criteria

• Hypothyroidism, hyperprolactinaemia (defined as serum prolactin levels greater than 25 ng/mL)
• Cushing's syndrome
• Nonclassical congenital adrenal hyperplasia (defined as serum 17-hydroxyprogesterone levels greater than 1.2 and 5.2 ng/mL in the follicular and luteal phase, respectively) and current or previous (within the last three months) use of oral contraceptives and other hormonal
• Antidiabetic and antiobesity drugs.